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Ubiquitination: RING for destruction?
Paul S. Freemont
Ubiquitination targets proteins for degradation and is
a potent regulator of cellular protein function. Recent
results implicate the RING finger domain in specific
ubiquitination events; it is possible that all RING proteins
act as E3 ubiquitin protein ligases, with implications for
a variety of biological areas.
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Targeted protein proteolysis is increasingly understood to
be an important general mechanism by which cells
regulate protein levels — and consequently their functions
at specific times. In eukaryotic cells, the main mechanism
for such control involves the specific covalent modification
by polyubiquitin, which labels target proteins for proteoly-
sis and subsequent degradation. There are many known
examples of such events, and ubiquitination is now recog-
nised as a major mechanism for cellular regulation, perhaps
even vying with phosphorylation in general importance.
But how does the cell know which proteins to target? 
We have already begun to identify multiprotein complexes,
known as E3 ubiquitin protein ligases, that function in
choosing specific targets for ubiquitination. These E3 pro-
teins bind to both target proteins and the ubiquitin E2
conjugating enzymes, thereby selecting and promoting
ubiquitination. These complexes are few and far
between, however, but recent studies on several different
proteins that contain a domain called the RING finger
have now provided significant insights into how ubiquitin
targeting can be achieved [1–4]. The RING finger is a
small zinc-binding domain found in many functionally
distinct proteins, which up until now had no known
general function. The new studies have now shown that
the RING finger can specifically interact with E2 ubiqui-
tin conjugating enzymes, thereby promoting ubiquitina-
tion, and that proteins which contain a RING finger may
act as E3 ubiquitin protein ligases.
The RING finger protein sequence motif was first
identified nearly ten years ago in the protein product of
the human gene RING1 — Really Interesting New Gene 1 —
which is located proximal to the major histocompatibility
region on chromosome 6. Although the domain was ini-
tially identified in only a few functionally distinct pro-
teins, the set of proteins known to have RING fingers has
grown enormously over the last few years, and the motif
and its variants have been found in more than 200 proteins
from diverse eukaryotes, but interestingly not in any
prokaryote protein (reviewed in [5]). Perhaps the most
famous RING finger protein is BRCA1, product of a
breast cancer-associated gene; point mutations within the
RING finger domain of BRCA1 predispose females carry-
ing them to breast cancer. Other family members are also
well known, however; for example, the family includes the
protooncogene products Cbl, BMI-1 and PML, the
immunoglobulin gene recombination enzyme RAG1, the
Rbx1 component of the VHL tumour suppressor complex,
and the p53 regulator MDM2, to name but a few [5].
The RING finger motif can be defined as a unique linear
series of conserved cysteine and histidine residues:
Cys–X2–Cys–X9–39–Cys–X1–3–His–X2–3–Cys/His–X2–Cys–
X4–48–Cys–X2–Cys, where X can be any amino acid,
although there are distinct preferences for particular types
of amino acid at particular positions [5]. Apart from the
absolutely conserved cysteine and histidine residues,
there is little sequence conservation, unlike other cys-
teine-rich motifs. Initial structural and biophysical studies
have confirmed, that like these other motifs, the RING
finger binds zinc atoms. In particular, the RING finger
binds two zinc atoms in a unique ‘cross-brace’ arrange-
ment; the conserved spacing between the second and
third pairs of cysteine/histidine residues implies conserva-
tion of the distance between the two zinc-binding sites.
Indeed this is the case, as shown by several three-dimen-
sional RING finger structures that show the motif to fold
into a compact autonomously folded domain comprising a
small central β sheet and an α helix in some cases, with an
inter-zinc distance of ~14 Å in all cases (reviewed in [5]). 
There are a few other interesting features of RING fingers
that are worth mentioning. RING fingers and their variants
are generally found close to an amino or carboxyl terminus.
Interestingly, RING-H2 motifs — where the fourth cys-
teine is replaced with a histidine — are often found close to
a carboxyl terminus, although there are no hard and fast
rules. RING fingers can also be associated with other
domains to form larger conserved motifs, such as the
RING finger–B box–α-helical coiled-coil (RBCC) motif [5].
Despite all the detailed information available on RING
fingers, a number of important questions about them
have, until recently at least, remained unanswered. The
most important of these is the key question of what is the
function of the RING finger domain? And why are RING
fingers found in such a variety of proteins? Can we attribute
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a common function to the RING finger? And if we can,
how do we account for the variation in sequence, size and
structure of the domain? 
Early results did indicate that RING fingers are essential
for the normal functioning of the proteins that contain
them. For example, studies on the TRAF proteins, which
transduce signals from members of the tumour necrosis
factor (TNF) receptor superfamily to the transcription
factor NF-κB, showed that deletion or mutation of the
cysteine residues in their RING finger domains abrogate
TNF receptor signalling [6]. Other studies identified
protein–protein interactions that depend on the RING
finger domain — for example, BRCA1 and the protein
BARD1 were shown to interact via the two proteins’
RING finger domains [7]. These observations were inter-
esting, but did not provide general insights into the func-
tion or mechanism of action of the RING finger. This
situation is now changing, as over the last year or so a
number of results have indicated that the RING finger is
involved in the ubiquitination pathway. This has culmi-
nated in several recent studies [1–4] which have for the
first time provided direct functional evidence that RING
fingers mediate ubiquitination events.
The ubiquitination pathway generally involves three
types of enzyme, know as E1, E2 and E3. E1 and E2 are
ubiquitin conjugating enzymes, which catalyse formation
of thioester bonds directly with the carboxyl terminus of
ubiquitin; an E1 enzyme acts first and passes ubiquitin to
an E2 enzyme ready for targeting to a protein substrate.
The E3 enzymes are ubiquitin protein ligases, responsible
for substrate recognition and promoting polyubiquitin lig-
ation to a substrate, marking it for degradation by the 26S
proteosome. E3 enzymes often bring together the acti-
vated E2~ubiquitin adducts and the target substrates, and
they are thought to be the least conserved component of
the ubiquitination pathway. 
The functional connection between RING fingers and
ubiquitination has come primarily from studies on the
RING-containing protein Cbl. This protein is an impor-
tant negative regulator of several signalling pathways that
are activated through the receptor for platelet-derived
growth factor (PDGF), epidermal growth factor (EGF) or
colony stimulating factor. Cbl is of interest to cancer
researchers, as the protein becomes oncogenic in vivo as a
result of mutation or deletion of the RING finger. In addi-
tion to the RING, Cbl also has a variant SH2 domain and a
proline-rich region, all the hallmarks of an adaptor protein.
It is now generally accepted that Cbl works by promoting
polyubiquitination of receptor protein tyrosine kinases,
although until recently the precise molecular mechanisms
have been elusive.
Yarden and colleagues [1] have now shown that the
desensitisation of the EGF receptor that normally follows
its activation by ligand binding requires the Cbl RING
finger. They found that single cysteine mutations of the
RING finger produce dominant-negative forms of Cbl,
which bind to but do not downregulate activated receptors.
Baron and colleagues [2] have gone even further and shown
that the Cbl RING finger interacts with the E2 ubiquitin
conjugating enzyme UbcH7, thereby mediating the ubiqui-
tination of the EGF receptor in vivo in a ligand-dependent
manner. Hunter and colleagues [3] have dissected Cbl
function further. They have shown that the ubiquitination
of receptor tyrosine kinases is directly dependent on both
the SH2 and RING finger domains of Cbl. Furthermore,
they have demonstrated that the Cbl RING finger specifi-
cally recruits, and allosterically activates, the E2 ubiquitin
conjugating enzyme UbcH4. From these observations they
made the startling conclusion that Cbl actually acts as an E3
ubiquitin protein ligase [3]; that is, Cbl recognises tyrosine
phosphorylated substrates, such as PDGF receptor, via its
SH2 domain and then recruits and activates E2 ubiquitin
conjugating enzymes via its RING finger.
Figure 1
RING finger domains mediate specific
interactions with components of the
ubiquitination pathway. RING-containing
proteins are named alongside arrows that
indicate their specific RING-mediated
interactions. (See text for details.)
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In their study, Weissman and colleagues [4] identified a
novel RING-containing protein, AO7, in a yeast two-
hybrid screen using as bait the human E2 ubiquitin-conju-
gating enzyme UbcH5. They then proceeded to show that
AO7 itself acts as a substrate for polyubiquitination by
binding directly to the E2 enzyme via its RING-H2
domain. More importantly perhaps, they also tested a
number of unrelated proteins containing RING fingers for
E2-mediated autoubiquitination activity and somewhat
surprisingly, they found that in all cases RING and
RING-H2 domains appeared functional [4]. More recently
Robinson and colleagues [8] have also reported a specific
interaction between a RING finger protein and an E2
enzyme. By using the human E2 conjugating enzyme
UbcH7 as bait in a yeast two-hybrid screen, they isolated
two novel RING-containing proteins, one of which,
HHARI, interacts with UbcH7 via its RING finger in
vitro. By testing other E2s, they found that only the highly
related enzyme UbcH8 interacted with HHARI, support-
ing a specific RING-E2 interaction [8]. 
Recent studies have thus identified several examples of
specific RING-mediated E2 interactions (Figure 1). The
obvious question they raise is whether all RING-contain-
ing proteins act as E3 ubiquitin-protein ligases? The Cbl
story provides direct evidence for a RING-mediated E3
activity, but several other directly relevant observations
were reported earlier last year [9–11]. These studies
defined a new component of the SCF ubiquitin ligase
complex — where SCF derives from the three compo-
nents Skip1, Cdc53 and F box protein — a modular multi-
protein complex that mediates ubiquitination and
subsequent degradation of a variety of different proteins,
including the G1 cyclins. The newly identified SCF
protein in question is Hrt1/Rbx1, which has a RING-H2
domain [9–11]. Hrt1/Rbx1 acts together with F box
proteins — substrate-targeting components of SCF
complexes — and stimulates the ubiquitin ligase activity of
several SCF complexes by promoting association of the E2
conjugating enzyme Cdc34 with Cdc53. Perhaps of more
significance is the fact that Hrt1/Rbx1 is strikingly similar
to the Apc11 subunit of the anaphase-promoting complex
(APC), an E3 ubiquitin ligase complex that plays an impor-
tant role in cell-cycle progression [9]. Very recently, studies
on another E2–E3 complex, Ubc2p–Ubr1p, have shown
that the RING-H2 domain of the E3 Ubr1p is necessary
for polyubiquitination but interestingly not for interaction
with the E2 Ubc2p [12]. 
An even higher profile player that has a variant RING finger
and acts as an E3 ubiquitin protein ligase now becomes very
relevant to the discussion. The protooncogene product
MDM2 is the critical cellular regulator of p53, determining
p53’s stability by binding directly to it and mediating its
ubiquitination and subsequent degradation. Perhaps not
surprising now, but highly relevant, is the observation
that MDM2’s variant RING finger is essential for its E3
activity [13]. It is very plausible that MDM2 uses the
variant RING finger to interact specifically with an E2
enzyme and thereby promote ubiquitination of p53. RING
finger proteins have thus now been found in several differ-
ent E3 complexes (Figure 2), and this may turn out to be
true of all RING finger proteins.
Over the last couple of years or so, a number of other
studies have implicated RING fingers in ubiquitination
events. For example, members of a novel family of RING
finger proteins have been reported to interact directly
with the ubiquitin-conjugating enzyme UbcM4 [14]. And
the RING-H2 domain of a protein known as Der3/Hrd1
has been implicated in protein degradation associated
with the endoplasmic reticulum in yeast [15]. Also of
interest is the observation that the RING domain of
Siah-1 — the human homologue of Seven in absentia, a
protein involved in eye development in Drosophila — is
required for proteolysis of several target proteins [16].
The RING finger protein PRT1 has been shown to be
required in plants for the degradation of short-lived pro-
teins with a particular amino acid at the amino terminus;
this amino acid acts as a destabilising tag, an example of
the ‘N-end rule’ ubiquitination pathway [17]. More
recently, the RING finger of the HSV protein Vmw110
has been shown to be essential for a virus-induced block
in mitosis in infected cells, which is directly correlated
with the proteosome-mediated degradation of the
CENP-C protein [18].
Figure 2
RING fingers are required for both E3 ubiquitin protein ligase activities
and ubiquitin-mediated proteolysis. The names indicate specific
RING-containing proteins, apart from SCF and APC which are
multiprotein complexes that contain the RING proteins APC11 and
Hrt1/Rbx1. Arrows indicate a direct involvement of the RING finger. 
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Taken together, these various observations provide
compelling evidence for the view that RING fingers have
a general function in ubiquitin-mediated proteolysis
(Figure 2). Several important questions still need to be
addressed, however. For example, is the role of RING
fingers in ubiquitination events limited to that of mediat-
ing specific interactions with E2 enzymes? Perhaps not, as
it has already been shown that the BRCA1 RING finger
mediates a direct interaction in vivo with a ubiquitin
carboxy-terminal hydrolase named BAP1 [19]. Is the func-
tion of the RING finger therefore limited to the general
ubiquitination pathway? Again perhaps not, as there is evi-
dence that the acute promyelocytic leukaemia protein
PML uses its RING finger to interact with an E2, UbcH9,
whose substrate is not ubiquitin, but a ubiquitin-like
protein known as SUMO-1 [20]. What is clear, however, is
that there is now a significant body of evidence supporting
the involvement of a number of different, and functionally
distinct, RING finger proteins in ubiquitin or ubiquitin-
like pathways and events.
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